that s the far right bloc that has been a persistent thorn in the pseudoof the leadership team. now with speaker johnson. they tended to try to scuttle this deal that johnson cut with chuck schumer. they believe d it spent too muc money and demanded for severe restrictions on the southern border with mexico. things that the the kras would not accept. johnson try ining to kut a deal tout some conservative victories. he was open to discussing the concerns of the far right members, but just moments ago, say that he would not side with those concerns and would stick to the agreement he cut with chuck schumer. when i asked bob good a about this, one of the eight members that kevin mccarthy was oust ed by. he made clear he was opposed to what johnson is doing, but he was not going to try to push johnson out of the speakership. how kiss adisappointed are yu
In an article published on Dec. 18, 2023, in Nature, researchers from the Centre for Genomic Regulation in Barcelona (Spain) and Wellcome Sanger Institute in Hinxton (U.K.) reported achieving a milestone regarding KRAS targeting in cancer. The team quantified the impact of >26,000 KRAS variants and how these mutations affected protein folding and its interaction with the six main effectors – RAF1, PIK3CG, RALGDS, SOS1, K27 and K55.
Shared insight into the comprehensive list of molecular targets in metastatic NSCLC, from point mutations like EGFR and KRAS to fusions such as ALK and ROS1, understanding the challenges of comprehensive testing and treatment implications.
A comprehensive study exploring NSCLC subgroup responses to immunotherapy may help determine which patients are less likely to benefit from these agents.